cinoxacin has been researched along with Pyelonephritis in 4 studies
Cinoxacin: Synthetic antimicrobial related to OXOLINIC ACID and NALIDIXIC ACID and used in URINARY TRACT INFECTIONS.
cinoxacin : A member of the class of cinnolines that is 6,7-methylenedioxycinnolin-4(1H)-one bearing an ethyl group at position 1 and a carboxylic acid group at position 3. An analogue of oxolinic acid, it has similar antibacterial actions. It was formerly used for the treatment of urinary tract infections.
Pyelonephritis: Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomised single-blind clinical trial compared cinoxacin (500 mg every 12 hours) to co-trimoxazole (160 mg trimethoprim, 800 mg sulphamethoxazole every 12 hours) in the treatment of 63 patients with urinary tract infections." | 9.05 | Comparison of cinoxacin and co-trimoxazole in the treatment of urinary tract infections. ( de Jersey, P; Wooller, HO, 1982) |
| "The antimicrobial activity of cinoxacin, 1-ethyl-4(1H)-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid, previously reported as compound 64716, was determined and compared with other antimicrobial agents at a dosage of 12 mg/kg once daily in a descending pyelonephritis rat model with Escherichia coli and Proteus mirabilis as infecting organisms." | 7.65 | Cinoxacin: effectiveness against experimental pyelonephritis in rats. ( Ensminger, PW; Gordee, RS; Holmes, DH, 1974) |
| "A randomised single-blind clinical trial compared cinoxacin (500 mg every 12 hours) to co-trimoxazole (160 mg trimethoprim, 800 mg sulphamethoxazole every 12 hours) in the treatment of 63 patients with urinary tract infections." | 5.05 | Comparison of cinoxacin and co-trimoxazole in the treatment of urinary tract infections. ( de Jersey, P; Wooller, HO, 1982) |
| "The antimicrobial activity of cinoxacin, 1-ethyl-4(1H)-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid, previously reported as compound 64716, was determined and compared with other antimicrobial agents at a dosage of 12 mg/kg once daily in a descending pyelonephritis rat model with Escherichia coli and Proteus mirabilis as infecting organisms." | 3.65 | Cinoxacin: effectiveness against experimental pyelonephritis in rats. ( Ensminger, PW; Gordee, RS; Holmes, DH, 1974) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Jersey, P | 1 |
| Wooller, HO | 1 |
| Briedigkeit, H | 1 |
| Schimmelpfennig, R | 1 |
| Buder, R | 1 |
| Precht, K | 1 |
| Dröseler, H | 1 |
| Hayashi, Y | 1 |
| Terao, E | 1 |
| Yamasaki, I | 1 |
| Holmes, DH | 1 |
| Ensminger, PW | 1 |
| Gordee, RS | 1 |
2 trials available for cinoxacin and Pyelonephritis
| Article | Year |
|---|---|
Comparison of cinoxacin and co-trimoxazole in the treatment of urinary tract infections.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents, Urinary; Bacteriuria; Cinoxacin; Clinical Trials as | 1982 |
[A comparison of cinoxacin and nalidixic acid in the treatment of chronic urinary tract infections].
Topics: Bacteriuria; Chronic Disease; Cinoxacin; Cystitis; Gastrointestinal Diseases; Humans; Nalidixic Acid | 1982 |
2 other studies available for cinoxacin and Pyelonephritis
| Article | Year |
|---|---|
[Study of clinical efficacy and safety of long-term cinoxacin therapy of chronic urogenital organ infection].
Topics: Adult; Aged; Chronic Disease; Cinoxacin; Drug Evaluation; Female; Humans; Male; Middle Aged; Prostat | 1987 |
Cinoxacin: effectiveness against experimental pyelonephritis in rats.
Topics: Animals; Cinoxacin; Escherichia coli; Escherichia coli Infections; Female; Microbial Sensitivity Tes | 1974 |